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A Flexible Joint Longitudinal-Survival
Modeling Framework for Incorporating
Multiple Longitudinal Biomarkers
Sepehr Akhavan-Masouleh, Alexander Vandenberg-Rodes,
Babak Shahbaba, and Daniel L. Gillen
Abstract: We are interested in survival analysis of hemodialysis patients
for whom several biomarkers are recorded over time. Motivated by this
challenging problem, we propose a general framework for multivariate joint
longitudinal-survival modeling that can be used to examine the associa-
tion between several longitudinally recorded covariates and a time-to-event
endpoint. Our method allows for simultaneous modeling of longitudinal
covariates by taking their correlation into account. This leads to a more
efficient method for modeling their trajectories over time, and hence, it can
better capture their relationship to the survival outcomes.
Keywords and phrases: Proportional Hazard models, Gaussian pro-
cesses, Dirichlet process mixture models.
1. Introduction
In this paper, we aim to examine the association between mortality and the
longitudinal measurements of several biomarkers among hemodialysis patients.
We are specifically focusing on the data obtained from a 5-year (January 2007-
December 2011) cohort of 109,718 hemodialysis patients who were treated for
dialysis in dialysis clinics in the United States. The dataset was studied in detail
by Ravel et al. (2015). In such studies, it is common to measure multiple longi-
tudinal biomarkers during the study follow up. Collected longitudinal measures
on each subject tend to be correlated and temporally dependent as they are
taken on the same subject. One could of course model the trajectory of each
biomarker independently from other collected biomarkers. However, by simulta-
neously modeling the trajectory of all biomarkers, one can take the correlation
between the different biomarkers into account. This could lead to a more precise
model of biomarker trajectories. More specifically, when some biomarkers are
measured less frequently compared to the other biomarkers (e.g., if they are
difficult or expensive to measure), simultaneously modeling biomarkers can be
particularly useful as one can gain more precision in estimating less frequent
biomarkers by taking the correlation between all biomarkers into account and
by borrowing information from the higher frequency biomarkers to better pre-
dict the lower frequency ones. Finally, a joint longitudinal-survival model with a
flexible longitudinal component, which is capable of modeling the trajectory of
multiple biomarkers simultaneously, can be used to test the association between
the survival outcome and the longitudinal biomarkers.
1
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Throughout this paper, we shall use the word ”joint” when we model longitudinal-
survival data simultaneously. We reserve the word ”simultaneous” to refer to
modeling multiple longitudinal measures at a same time rather than modeling
each biomarker trajectory independently from others.
1.1. Some Related Methods
Simultaneously modeling longitudinal biomarkers can be considered in the con-
text of a multivariate temporal process model that can be used both for infer-
ential purposes as well as prediction and interpolation purposes. In order to de-
velop such model, specification of a valid cross-covariance function is necessary.
A valid cross-covariance function is required to lead to a valid positive-definite
covariance matrix for any number of time points and at any choice of these time
points (Gelfand and Banerjee, 2010). A common cross-covariance function is to
use separable cross-covariance function construction that shall be explained in
more detail in Section 3.
The question of describing the correlation between multiple longitudinal
measures has been addressed from a different perspective in geostatistics lit-
erature with a focus on spatial data. Bernardo et al. (1998) and Berger et al.
(2003) described the kernel convolution technique for creating stationary and
non-stationary spatial processes. Majumdar and Gelfand (2007) proposed pro-
ducing cross-covariance functions by using convolution of covariance functions.
Multivariate models in geostatistics started with Matheron (1973) and by in-
troduction of some new concepts including cross-variogram and co-Kriging.
Gelfand and Banerjee (2010) defined co-Kriging as a spatial prediction method
that uses both the information of the process being considered as well as the in-
formation from other related processes. Co-Kriging is commonly addressed in the
context of the linear models as these models are easily interpreted. These models
that are commonly known as linear model of co-regionalization (LMC) have been
considered widely in the literature including Grzebyk and Wackernagel (1994),
Schmidt and Gelfand (2003), and Ver Hoef, Cressie and Barry (2004).
In a different work, we proposed a flexible joint longitudinal-survival Model-
ing framework for quantifying the association between a longitudinal biomarker
and Survival Outcomes (Akhavan et al., 2018). We are now interested in ex-
tending our method to be able to model multiple biomarkers simultaneously.
In Section 2, we will show how a Gaussian process model can be extended to
a multivariate Gaussian process to model multiple longitudinal biomarkers si-
multaneously. In Section 3, using our proposed multivariate Gaussian process,
we build a joint longitudinal-survival model capable of relating longitudinal
biomarkers to survival outcome. In Section 4, we use several simulation studies
to evaluate our proposed model. Section 5 presents our data analysis results.
2. Multivariate Gaussian Process
Consider the function f that relates an input space T to an output space X .
As an alternative to an explicit functional assumption on f , one can assume
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a Gaussian process prior on f . One may consider time as the input space and
the space of a longitudinal measure X as the output space and may use Gaus-
sian process prior as a prior on all plausible functions f relating time t to the
longitudinal measure X at time t.
X(t) = f(t) + ǫ
f ∼ GP (µ(t), Cf (t, t
′))
In the setting above, f is considered as a univariate function with one output
at each time point t. In general, however, f can be a multivariate function with
a vector of outputs at each time t. A multivariate function f will require a
multivariate Gaussian process prior. One can consider a more general frame
work of the following form
X(t) = f (t) + ǫ,
f(t) ∼ GP (µf (t),Cf (t, t
′)),
where X(t) is a vector of outputs at time t, f is a multivariate function with
a multivariate Gaussian process prior with a mean vector function µf (t) and a
cross-covariance matrix function Cf (t, t
′).
Consider a multivariate longitudinal vectorX(t) at time t with the dimension
q×1. Without loss of generality and for simplicity of the notations, we assume a
multivariate longitudinal random vector with mean zero, E[X(t)] = 0. A cross-
covariance function between two generic time points t and t′ is a matrix function
with dimension q × q where the (i, j)th element of this matrix is defined as
Cij(t, t
′) = Cov
(
Xi(t), Xj(t
′)
)
= E[Xi(t)Xj(t
′)]− E[Xi(t)]E[Xj(t
′)]
= E[Xi(t)Xj(t
′)], (2.1)
where E[Xi(t)] and E[Xj(t
′)] are 0. Equation (2.1) indicates that the cross-
covariance matrix function C(t, t′) can be defined as
C(t, t′) = E[X(t)X(t′)
T
]. (2.2)
Consider n arbitrary time points {t1, t2, . . . , tn}. At each time point ti, X(ti) is
a q × 1 vector. Concatenating n such output vectors, one can define an nq × 1
vector X, where X = [X(t1),X(t2), . . . ,X(tn)]. Random vector X is mean-
zero with a covariance matrix ΣX with the dimension nq × nq. ΣX is a block
matrix where each block is the cross-covariance matrix corresponding to time ti
and tj for all q outputs at each time point.
As a covariance matrix, ΣX has to be symmetric and positive definite. As
Gelfand and Banerjee (2010) showed, this requires the covariance matrix func-
tion C(t, t′) to satisfy the two following conditions of
1. C(t, t′) = CT (t, t′),
2. for any integer value n and for any arbitrary collection of ”n” time points:∑n
i=1
∑n
j=1X
T (ti)C(ti, tj)X(tj) > 0.
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A multivariate processX(t) is stationary if the cross-covariance matrix func-
tion depends only on the time difference between t and t′, where we can write
C(t, t′) = C(t′ − t). Multivariate process X(t) is called isotropic if the cross-
covariance matrix function depends only on the absolute difference between
t and t′, where we can write C(t, t′) = C(|t′ − t|). Yadrenko (1987) showed
that under isotropic condition, a covariance function Cij(h) will form a valid
cross-covariance matrix function if and only if the Cij(h) function for a positive-
definite measure F (.) has a cross-spectral representation of the form
Cij(h) =
∫
exp(2πitTh)d(Fij(t)).
Despite the existence of many methods proposed in the literature, when cross-
covariance functions are unknown, specification of a valid cross-covariance func-
tion based on the observed data is a very difficult task. One common approach
to specify a valid cross-covariance function is to use a class of covariance func-
tions known as separable cross-covariance structures that shall be introduced in
the next section.
Now considerX(t) as a vector of q longitudinal variables all measured at time
t. The cross-covariance matrix function C(t, t′) is then a q× q matrix where it’s
(i, j)th element is equal to Cij(t, t
′) that was defined in equation (2.1). One
can assume that the covariance between the q longitudinal variables at each
time-point remains the same at all time points t and can be specified with a
positive definite covariance matrix R. The correlation between measured values
at time t and measured values at time t′ can then be expressed using a univariate
correlation function ρ(t, t′). Given this specification, one can write
C(t, t
′) = ρ(t, t′)R, (2.3)
where R is of size q × q and represents the covariance matrix between the q
elements ofX(t) that remain the same at all time points t, and ρ(t, t′) represents
the correlation between measures at time t and measures at time t′.
Now consider n time points {t1, t2, . . . , tn} where at each time point ti,
we observe a stack of q longitudinal random variables X(ti). Consider X =
[X(t1),X(t2), . . . ,X(tn)]
T as the vertical stack of n longitudinal vectors, each
element of that vector is an observed X(ti) at a time point ti. Cov(X) can be
defined as
Cov(X) = R⊗ S, (2.4)
where the (i, j)th element of S is represented with Sij and is equal to Sij =
ρ(ti, tj), the notation ⊗ represents the Kronecker product, and R is the non-
temporal covariance function between the q longitudinal variables that is as-
sumed to remain the same across time points ti’s.
By using a separable cross-covariance function and given that R matrix is
positive definite by definition, with a positive definite matrix S, it’s guaran-
teed that Cov(X) will be positive definite. Furthermore, by using a separa-
ble cross-covariance structure, the determinant of the cross-covariance func-
tion, |Cov(X)|, and the inverse of the cross-covariance function,Cov(X)
−1
,
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will become computational convenient to deal with. In particular, by using
the properties of the Kronecker product, one can show that the determinant
of the cross-covariance can be written as |Cov(X)| = |R|q|S|n, where |R| and
|S| are the determinant of the R matrix and the determinant of the S, re-
spectively. Also, the inverse of the cross-covariance function can be written as
Cov(X)
−1
= R−1 ⊗ S−1. We shall use the class of separable cross-covariance
functions to setup our proposed model.
3. Joint Model
In this section, we first start by introducing the likelihood specification of our
joint model. We then continue with introducing the longitudinal component
of the model and the survival component. Our proposed method can work for
any number of longitudinal biomarkers, however, for the sake of simplicity of
the notations, we consider only two longitudinal biomarkers. We refer to the
first longitudinal biomarker with X(1) and to the second biomarker with X(2).
We denote survival outcome with Y . n refers to how many subjects are be-
ing followed up in the study. l
(1)
i and l
(2)
i refer to the number of longitudinal
biomarker 1 measures and biomarker 2 measures obtained for subject i at time
points t
(1)
ij , j = 1, 2, . . . , l
(1)
i and t
(2)
ik , k = 1, 2, . . . , l
(2)
i , respectively. Also, asso-
ciated with each subject, there is an observed survival time, Yi ≡ min{Ti, Ci}
and event indicator δi ≡ 1[Yi=Ei], where Ti and Ci denote the true event time
and the censoring time for subject i, respectively. Further, we make the common
assumption that Ci is independent of Ti for all i, i = 1, . . . , n.
We define the contribution of each subject to the joint model likelihood as the
multiplication of the likelihood function of the longitudinal measures for that
subject and her/his time-to-event likelihood that is conditioned on her/his lon-
gitudinal measures. Let f
(i)
L , f
(i)
S|L, and f
(i)
L,S denote the longitudinal likelihood
contribution, the conditional survival likelihood contribution, and the joint like-
lihood contribution for subject i. One can write the joint longitudinal-survival
likelihood function as
fL,S =
n∏
i=1
f
(i)
L,S =
n∏
i=1
(
f
(i)
L × f
(i)
S|L
)
. (3.1)
In what follows, we explain the components of this model.
3.1. Longitudinal Component
We motivate the development of the multivariate Gaussian process model of
two longitudinal biomarkers by first considering the following simple model for
a single subject[
X
(1)
i
X
(2)
i
]
|
[
β
(1)
i0
β
(2)
i0
]
∼ N(
[
β
(1)
i0
β
(2)
i0
]
,Σǫ =
[
Σ(1) 0
0 Σ(2)
]
). (3.2)
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For simplicity of the notation, we assume that both biomarkers are measured si-
multaneously, that means at each time point t, we get to obtain measures on both
biomarkers. Our method is not limited to this assumption and once readers are
introduced with the model, we shall extend the notation to a model with no such
assumption. We define li as the number of longitudinal measures per biomarker.
These measures are obtained at an arbitrary time points ti1, ti2, . . . , tili . In the
equation (3.2), X
(1)
i and X
(2)
i are vectors of longitudinal biomarker 1 measure-
ments and longitudinal biomarker 2 measurements, each of size li × 1 respec-
tively. We shall stack X
(1)
i and X
(2)
i together into a column vector Xi that is
of size 2li × 1. β
(1)
i0 is a vector of repeated random intercepts corresponding to
biomarker 1 and β
(2)
i0 is a vector of repeated random intercepts corresponding to
biomarker 2, each of size li× 1. Also, we shall stack β
(1)
i0 and β
(2)
i0 into a column
vector β
(L)
i0 of size 2li × 1. The model in equation (3.2) assumes biomarker 1
and biomarker 2 are independent and each biomarker has its own measurement
error matrix. We consider Σ(1) = σ21Ili×li and Σ
(2) = σ22Ili×li , where σ
2
1 and σ
2
2
are shared parameters across all subjects.
By adding a stochastic component that is indexed by time to the model in
equation (3.2), we can relax the independence assumption between biomarkers
and we can also extend the model to capture non-linear patterns over time.
Specifically, we consider a stochastic vector, W , that is a realization from a
multivariate Gaussian process prior,W (t), that is mean zero and has a separable
cross-covariance function. Thus for subject i,Wi ∼ N2li(0, C
i
2li×2li
), whereWi
is a column vector that includes a stack of W
(1)
i and W
(2)
i , where W
(1)
i =
(Wti1 ,Wti2 , . . . ,Wtili ) and W
(2)
i = (Wti1 ,Wti2 , . . . ,Wtili ).
We characterize the covariance function, Cov(Wi), using a separable cross-
covariance structure as
Cov(Wi) = R⊗ Si, (3.3)
where R is a 2 by 2 matrix that characterizes the the covariance between the two
biomarkers and is assumed to be time-invariant, and Si is a temporal covariance
matrix. The R matrix is shared across all subjects with elements R11 and R22
characterizing marginal variances of the first and the second biomarker processes
respectively, and with the R12 element characterizing the covariance between the
two processes. In specific, one can decompose the covariance matrix R into the
following form
R =
[
τ1 0
0 τ2
]
Ω
[
τ1 0
0 τ2
]
, (3.4)
where τ1 and τ2 are square-root of the within biomarker 1 and biomarker 2
variances and Ω is a correlation matrix. Commonly, τ1 is set to equal 1 where
in that case, it’s assumed that Si will also capture the within biomarker 1
variability and τ2 is treated as a parameter indicating the relative biomarker
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variability between biomarker 2 and biomarker 1. Hence, we define
τ =
[
1 0
0 τ2
]
.
We re-write the equation (3.5) as
R = τΩτ. (3.5)
Si is the covariance matrix characterizing how longitudinal measures change over
time. Under the separable cross-covariance structure, we assume both biomark-
ers share the same covariance structure for changes in their values over time.
We characterize Si as an li × li matrix with elements Si(j, j
′) that is defined as
Si(j, j
′) = κi
2e−ρ
2(tij−tij′ )
2
, (3.6)
where the hyperparameter ρ2 controls the correlation length, and κ2 controls
the height of oscillations (Banerjee et al. 2004), and tij and tij′ are two different
time points. For notational simplicity, we define Ki = e
−ρ2(tij−tij′ )
2
; j, j′ ∈
{1, . . . , li}. We can extend the longitudinal model in equation (3.2) to the flexible
model below
Xi|β
(L)
i0 ,Wi, σ
2
1 , σ
2
2 ∼ N(β
(L)
i0 +Wi,Σǫ), (3.7)
where Wi is a stochastic vectors sampled from a Gaussian process prior of the
form
Wi|κi
2, ρ2 ∼ GP (0,R⊗ Si). (3.8)
In the model defined by equation (3.7), σ21 and σ
2
2 are assumed to be com-
mon across all subjects. Also, we assume the correlation length ρ2 is fixed and
hence, the subject-specific parameter κi
2 will have the role of capturing the
within-subject volatility of the longitudinal biomarkers. Finally, the longitudi-
nal component of our proposed joint model can be written as
Xi|Wi, β
(1)
i0 , β
(2)
i0 , κi
2, ρ2, σ21 , σ
2
2 ∼ N(β
(L)
i0 +Wi,Σǫ)
β
(1)
i0 ∼ N(µβ(1)0
, σ2
β
(1)
0
)
β
(2)
i0 ∼ N(µβ(2)0
, σ2
β
(2)
0
)
σ21 ∼ log −Normal(µσ21 , σσ21 )
σ22 ∼ log −Normal(µσ22 , σσ22 ) (3.9)
Wi|κi
2, ρ2, ti ∼ GP (0, R⊗ Si)
κi
2 ∼ log −Normal(µκ2 , σκ2)
τ2 ∼ Cauchy(0, λ0)
Ω ∼ LKJcorr(ν0),
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where β
(1)
i0 and β
(2)
i0 are random intercepts associated with biomarker 1 and
biomarker 2, respectively. β
(L)
i0 is a column vectors of size 2li× 1 that is a stack
of β
(1)
i0 and β
(2)
i0 each repeated li times. Finally, R matrix was decomposed based
on the equation (3.5).
3.2. Survival Component
Our goal is to quantify the association between the longitudinal biomarkers of
interest and the time-to-event outcomes by directly adjusting for biomarkers
measured values in a survival component of our proposed joint model. While
usually biomarkers are measured on a discrete lab-visit basis (ex. every month),
the event of interest happens on a continuous basis. While common frequentist
models use the so-called ”last-observation-carried” forward, by jointly modeling
longitudinal-survival data, one can properly impute biomarker measures at each
individual’s event time. In particular and from the Bayesian modeling perspec-
tive, in each MCMC iteration, given the sampled parameters for each individual
and by using the flexible multivariate Gaussian process in the longitudinal com-
ponent of the model, there exists posterior trajectories of biomarkers for each
individual. Our method, then, considers the posterior mean of those trajectories
as the proposed trajectory for each individual’s biomarker values over time at
that iteration. The posterior mean trajectories of our biomarkers of interest,
then, can be used to impute time-dependent biomarker covariates inside the
survival component of the model.
In order to quantify the association between two longitudinal biomarkers,
which are modeled simultaneously using the longitudinal component of the
model, and the time-to-event outcomes, we define our survival component by
using a multiplicative hazard model with the general form of
λ(Ti|Zi
(s),Zi
(L)) = λ0(Ti)exp{ζ
(s)Zi
(s) + ζ(L)Zi
(L)(t)},
where Ti is the event time for subject i, λ0(Ti) denotes a baseline hazard func-
tion, Zi
(s) is a vector of baseline covariates, Zi
(L) are longitudinal covariates
from the longitudinal component of the model, and ζ(S) and ζ(L) are regres-
sion coefficients interpretable as the log relative risk of ”death” per every unit
increase of their corresponding covariates.
We consider a Weibull distribution for the survival component to allow for
log-linear changes in the baseline hazard function over time. Thus we assume
Ti ∼ Weibull(ν, λi), (3.10)
that means
f(Ti|ν, λi) = νTi
ν−1exp
(
λi − exp(λi)Ti
ν
)
. (3.11)
Weibull distribution is available in closed form and can be evaluated compu-
tationally efficiently. Under this parameterization of the Weibull distribution,
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covariates can be incorporated into the model by defining λi = ζ
(s)Zi
(s) +
ζ(L)Zi
(L), where ζ(s) are coefficients associated with baseline survival covari-
ates Zi
(s), and ζ(L) are longitudinal coefficients associated with longitudinal
covariates Zi
(L).
In particular, we are interested in a model that directly includes the two
longitudinal biomarker values at time t as a covariate inside the survival model.
Hence, we define our model as
Ti|ν, ζ
(s), ζ(X
(1)), ζ(X
(2)),Zi
(s), X
(1)
i (Ti), X
(2)
i (Ti) ∼Weibull(ν, λi), (3.12)
with
λi = β
(s)
i0 + ζ
(s)Zi
(s) + ζ(X
(1))X
(1)
i (Ti) + ζ
(X(2))X
(2)
i (Ti),
where ν is a common shape parameter shared with all subjects. β
(s)
i0 is a sub-
ject specific coefficient in the model which allows subject-specific baseline haz-
ard. Zi
(s) and ζ(s) are baseline covariates and their corresponding coefficients,
respectively. Finally, ζ(X
(1)) and ζ(X
(2)) are coefficients linking the longitudi-
nal biomarker1 value X
(1)
i (Ti) at time Ti and longitudinal biomarker2 value
X
(2)
i (Ti) at time Ti to the hazard for mortality, respectively.
In order to fit a fully joint longitudinal-survival model, at each iteration of
the MCMC and for a time-point t∗, predicted biomarker1 and biomarker2 values
for individual i are of the following form
X∗|Xi, t, t
∗ ∼ N2(µ
∗,Σ∗),
where X is a 2 × 1 vector where its first element is the predicted value of the
first biomarker and its second element is the predicted value for the second
biomarker. Xi is a column vectors of size 2li × 1 that represents the observed
biomarker values, where its first li elements are the observed biomarker1 values
and the remaining elements are the observed biomarker2 values. t is column
vector of size li that includes all time points at which values of the biomarkers
were observed. t∗ is the time at which by using the posterior trajectory of
biomarkers at each MCMC iteration, we want to impute a predicted value per
biomarker. Given our proposed longitudinal component setup, X is distributed
bivariate Normal with mean µ∗ and with covariance matrix Σ∗ that are of the
following forms
µ∗ = βLi0 +K(t
∗, t)KX
−1(Xi − β
(L)
i0), (3.13)
Σ∗ =K(t∗, t∗)−K(t∗, t)KX
−1K(t∗, t)′, (3.14)
where
K(t∗, t) = R ⊗ κi
2e−ρ
2(t∗−t)2 ,
K−1X = (R ⊗ Si +Σǫ)
−1, (3.15)
K(t∗, t∗) = R ⊗ S∗i ,
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where R and Si were defined earlier in Section 3.1. S
∗
i is defined similarly as Si
except that t is replaced with t∗. βLi0 is a column vector size 2 by 1 with random
intercept of the first biomarker, β
(1)
i0 , as its first element and random intercept
of the second biomarker, β
(2)
i0 , as it’s second element. β
(L)
i0 is a column vector
of size 2li × 1, where the first li elements are all the random intercept for the
first biomarker and the remaining li elements are all the random intercept for
the second biomarker.
In order to avoid an explicit distributional assumption on the survival times,
we specify our survival model as an infinite mixture of Weibull distributions
mixed on the β
(s)
i0 parameter. To do so, we use the Dirichlet process mixture of
Weibull distributions defined as
β
(s)
i0 |µi, σ
2
β
(s)
0
∼ N(µi, σ
2
β
(s)
0
), (3.16)
µi|G ∼ G, (3.17)
G ∼ DP
(
α(S), G0), (3.18)
where σ2
β
(s)
0
is a fixed parameter, µi is a subject-specific mean parameter from
a distribution G with a DP prior, α(S) is the concentration parameter of the
DP and G0 is the base distribution. By using the Dirichlet process prior on the
distribution of β
(s)
i0 , we allow patients with similar baseline hazards to cluster to-
gether which subsequently provides a stronger likelihood to estimate the baseline
hazards. For other coefficients in the survival model, we assume a multivariate
normal prior as
(
ζ(s), ζX
(1)
, ζX
(2))
∼ MVN(0,Σ = σ0
2I),
where ζ(s) is a set of coefficients associated with the baseline survival covariates,
ζX
(1)
and ζX
(2)
are coefficients associated with value of the first and the second
biomarkers respectively, σ0
2 is a prior variance for each coefficient, and I is the
identity matrix.
For the shared shape parameter ν, we consider a log-Normal prior, ν ∼
LogNormal(aν, bν), and specify the prior on the concentration parameter of
our DP model to be α(S) ∼ Γ(a
(S)
α , b
(S)
α ).
Finally, since the hazard function includes time-varying covariates, evaluation
of the log likelihood that involves integration of the hazard function over time is
done using the rectangular integration discussed in detail in our previous paper
(Akhavan et al., 2018). More details on posterior sampling and implementation
of our method are provided in Appendix A.
4. Simulation Studies
In this section, in order to evaluate our proposed model, we provide two types of
simulations. Type I simulations (4.1) only consider the longitudinal component
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of the model and are aimed to show the benefit of simultaneously modeling mul-
tiple longitudinal biomakers as opposed to modeling biomakers each separately.
We shall refer to the former with multi and to the latter with uni. The second
type of simulations, type II (4.2), are aimed to evaluate the performance of the
proposed joint longitudinal-survival model.
4.1. Multivariate Gaussian Process Model vs. Multiple Univariate
Gaussian Processes
One natural question in modeling multiple biomarkers is whether there is any
benefit in modeling these biomakers simultaneously (multi) as opposed to mod-
eling each biomaker process independently (uni). Type I simulations are design
to evaluate our proposed multi model vs. an alternative uni model.
We generate synthetic data for two biomakers of albumin (X(1)) and BMI
(X(2)). Albumin and BMI values are simulated off of the multivariate Gaussian
process model for 100 subjects and for each subject 60 albumin and 60 BMI
values. The multivariate Gaussian model is of the following form (more details
in the appendix A.1):
Xi|β
(L)
i0 , σ
2
1 , σ
2
2 ∼ N(β
(L)
i0 ,R⊗ Si +Σǫ). (4.1)
The κ2i values are simulated from the Uniform(0, 1) distribution. β
albumin
0
and βBMI0 are simulated from the Normal(µ = 5, σ = 1) and the Normal(µ =
20, σ = 2) distributions, respectively. Measurement errors σ2albumin and σ
2
BMI
are both set to be equal to 0.3.
To explore the benefit of simultaneously modeling biomakers, we compare
our proposed methodology here against an alternative modeling framework
(Akhavan et al., 2018) that models biomarker processes independently. Our gen-
eral comparison scheme is to randomly remove some of the obtained simulated
biomarker values and treat them as missing. Then we use our fitted models in
order to predict missing biomaker values. Models then are compared in terms of
the prediction mean error (MSE) of the missing values. we consider the following
three real world scenarios:
1. Scenario 1: Comparison of the models in terms of the prediction MSE
and as a function of correlation between biomakers and the amount of
time overlap between missing biomarkers.
2. Scenario 2: Here we tackle the real world scenario where on biomarker
is observed less frequently compared to the other biomarker (ex. one
biomarker is more expensive or more difficult to measure).
3. Scenario 3: Is our proposed multivariate model capable of handling biomarker
processes with different volatility given that our methodology assumes
common κ2 values across biomarkers with κ2 as a common measure of
volatility?
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4.1.1. Scenario 1
Under this scenario, we remove one third of the biomarker values and treat them
as missing. These 20 values are removed in the three following ways:
1. When one biomarker is missing, the other biomarker is also missing (i.e.
100% missing overlap).
2. When one biomarker is missing, the other biomarker is observed (i.e. 0%
missing overlap).
3. Half of the times both biomarkers are missing and half of the times, when
one is missing, the other biomarker is observed (i.e. 50% missing overlap)
Table 1 shows the simulation results from 100 generated datasets where the
multi and uni models are compared in terms of the average prediction MSE and
as a function of biomarker correlations and missing values % overlap. Based
on the simulation result, by taking the between-biomarker correlations into ac-
count, multi model leads to a smaller overall MSE compared to the uni model.
In Table 1, %Dec. indicates the percentage decrease in MSE comparing the
multi model and the uni model. As expected, as the correlation between the
two processes increases, the multi model leads to a smaller MSE compared to
the uni model. When the percent overlap between missing values decreases, in-
dicating when one biomarker is missing, the other biomarker is more likely to be
observed, the information from one biomarker can help the multi model better
predict the missing biomarker, and hence, will lead to a smaller MSE.
4.1.2. Scenario 2
Under this simulation scenario, we consider the real world scenario where one
biomarker, due to the cost of the procedure or the difficulty of obtaining biomarker
measures, is measured less frequently compared to the other biomarker. We gen-
erate synthetic data for two biomarkers each with 60 measurements and at five
different correlation levels between the two biomarker processes. We then ran-
domly remove measurements from the first biomarker at the 20%, 50%, and 80%
rate. Models are then compared in terms of the prediction MSE of the missing
values. As the results in Table 2 show, the proposed multivariate model leads
to lower MSEs compared to the univariate model. As expected, as the correla-
tion between the two biomarker processes increases, multi model better takes
advantage of the information from one biomarker to predict the other and led
to a smaller MSE.
4.1.3. Scenario 3
In building our proposed multivariate longitudinal model, we assumed a sepa-
rable cross-covariance structure where the model assumes that different longi-
tudinal processes share the same temporal covariance. In particular, our model
assumes a shared volatility measure κ2 across different biomarkers. Obviously,
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Correlation 100% Overlap 50% Overlap 0% Overlap
ρ Multi Uni %Dec. Multi Uni %Dec. Multi Uni %Dec.
0.1 0.237 0.243 2.5% 0.202 0.206 1.9% 0.207 0.212 2.4%
0.3 0.201 0.207 2.9% 0.215 0.227 5.3% 0.206 0.217 5.1%
0.5 0.209 0.217 3.7% 0.209 0.228 9.3% 0.196 0.227 13.7%
0.7 0.207 0.217 4.6% 0.189 0.228 17.1% 0.185 0.235 21.3%
0.9 0.194 0.204 4.9% 0.158 0.219 27.9% 0.139 0.237 41.4%
Table 1
Scenario 1: Comparison of the multivariate model (multi) and the univariate model (uni) in
terms of prediction MSE and as a function of biomarker correlation ρ and the time-overlap
between missing biomarkers (% overlap).
Correlation 20% Freq. 50% Freq. 80% Freq
ρ Multi Uni %Dec. Multi Uni %Dec. Multi Uni %Dec.
0.1 0.410 0.420 2.4% 0.281 0.286 1.8% 0.181 0.185 2.2%
0.3 0.391 0.423 7.6% 0.248 0.261 5.0% 0.188 0.197 4.6%
0.5 0.343 0.413 17.0% 0.226 0.264 14.4% 0.165 0.187 11.8%
0.7 0.319 0.407 21.6% 0.222 0.266 16.6% 0.152 0.188 19.2%
0.9 0.294 0.397 26.0% 0.190 0.245 22.5% 0.126 0.189 33.3%
Table 2
Scenario 2: Comparison of the models in terms of the prediction MSE and as a function of
biomarker correlation ρ and how frequently less-observed biomaker has been actually
observed (% Freq).
Correlation 100% Overlap 50% Overlap 0% Overlap
ρ Multi Uni %Dec. Multi Uni %Dec. Multi Uni %Dec.
0.1 0.263 0.270 2.6% 0.250 0.260 3.9% 0.258 0.267 3.1%
0.3 0.247 0.256 3.6% 0.252 0.263 4.1% 0.249 0.265 5.9%
0.5 0.264 0.275 3.8% 0.232 0.250 6.9% 0.252 0.277 9.1%
0.7 0.236 0.247 4.4% 0.254 0.282 10.2% 0.207 0.243 14.7%
0.9 0.231 0.245 5.9% 0.211 0.254 16.8% 0.214 0.275 22.4%
Table 3
Scenario 3: Comparison of the models in terms of prediction MSE and as a function of
biomarker correlation ρ and the time-overlap between missing biomarkers (% overlap).
by using an independent univariate Gaussian processes model (Uni) one can
estimate different κ2 values for each biomaker process. We, however, claim that
despite a shared κ2 across longitudinal biomarkers in our proposed multivariate
model (Multi), the model is still robust as the model can capture the within-
biomarker variances through the R covariance matrix (equation (3.5)). To show
this, we simulate two longitudinal biomarkers with different volatility measure
κ2 values. Table 3 supports our claim as our proposed multi model still leads to
smaller MSEs compared to the uni model.
4.2. Simulation Studies on the Proposed Joint Multivariate
Longitudinal-Survival Model
Our second type of simulations are focused on evaluating the performance
of our proposed joint multivariate longitudinal-survival model. We simulated
200 datasets that resembled the real data on end-stage renal disease patients
that was obtained from the United States Renal Data System (USRDS). Each
dataset included 300 subjects. We simulated longitudinal trajectories for the
two biomarkers of albumin (X(1)) and BMI (X(2)), with 16 within subject al-
bumin and 8 within subject BMI measures. Both biomarkers are generated from
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a joint multivariate Gaussian process with a high-correlation of 0.9 between the
processes. In particular, biomarker measures for each subject i are simulated
from
Xi|β
(L)
i0 , σ
2
1 , σ
2
2 ∼ N(β
(L)
i0 ,R⊗ Si +Σǫ),
where β
(L)
i0 is a stack of two subject specific random intercepts for the two
processes. Subject-specific random intercepts for the albumins are simulated
from the Normal distribution N(µ = 5, σ2 = 1) and the random intercepts for
the BMIs are simulated from the Normal distribution N(µ = 20, σ2 = 4). σ21
and σ22 are both set to 0.3. Si is considered to be equal to Si = κ
2
iKi, where κ
2
i ’s
are simulated from the uniform U(min = 0,max = 1) distribution. Ki is the
distance matrix of the form exp{−ρ2(tij − tij′)}, with a fixed ρ
2 of 0.1 and time
points tij ’s that are sampled uniformly from a followup time with a maximum of
15 months. The R matrix is the covariance matrix of the two biomarkers with a
high correlation of 0.9 between the processes and with scaled variances for each
biomarker process. Survival times are generated from a Weibull distribution of
the form
Ti ∼Weibull(ν, λi),
with the shape parameter of the distribution, ν, set to 1.5 and the log-scale
parameter λi that is of the form
λi = β
(s)
i0 + ζ
(X(1))X
(1)
i (Ti) + ζ
(X(2))X
(2)
i (Ti),
where β
(s)
i0 were sampled from an equally weighted mixture of two Normal dis-
tributions of N(µ = −1.5, σ2 = 1) and N(µ = 1.5, σ2 = 1). ζ(X
(1)) is fixed to 0.5
and ζ(X
(2)) is fixed to -0.3. Censoring times are generated from a uniform dis-
tribution and independent of the survival times Ti with parameters that ensure
a 20% censoring rate.
In order to evaluate the performance of our proposed model, we also fit a
last-observation carried forward proportional hazard Cox model as well as an
alternative joint longitudinal-survival model that models biomarkers indepen-
dently (Akhavan et al., 2018).
Albumin and BMI random intercepts are assumed to have the priors N(µ =
5, σ2 = 4) and N(µ = 20, σ2 = 25), respectively. κ2i ’s are assumed to have the
log−Normal(−1, 2) prior. Both σ21 and σ
2
2 had the log−Normal(−1, 1) prior.
We assumed R matrix to be of the form τΩτ , where τ is a 2 × 2 matrix with
the diagonal elements of 1 and τ2 and Ω is the correlation matrix between the
two biomarkers that is of size 2 × 2. We consider a Cauchy(0, 2.5) prior on τ2
and an LKJ(1) prior on Ω. We put the log−Normal(0, 1) prior on the Weibull
shape parameter ν. We also consider independent N(µ = 0, σ2 = 25) priors on
ζ(X
(1)) and ζ(X
(2)). β
(s)
i0 are assumed to be distributed according to an unknown
distribution G with the Dirichlet process DP (α,G0) prior. We consider the
Γ(3, 3) prior on α and we consider G0 to be the standard Normal distribution
N(µ = 0, σ2 = 1).
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Covariate of True Conditional LOCF Cox Uni. Joint Model Multi Joint Model
Interest Estimand Mean SD MSE Mean SD MSE Mean SD MSE
Albumin(t) 0.5 0.242 0.089 0.077 0.443 0.124 0.012 0.481 0.101 0.009
BMI(t) -0.3 -0.135 0.055 0.027 -0.278 0.127 0.003 -0.287 0.109 0.003
Table 4
Coefficient estimates under different models along with the corresponding standard deviation
and mean-squared error values per estimated coefficient.
Table 4 shows the simulation results. As expected, the last observation car-
ried forward Cox model leads to estimates that are shrunk towards 0 as this
model is blind to the differential subject-specific baseline hazards that are in-
duced by subject-specific β
(s)
i0 values. The estimates under the Cox model are
marginalized over all subjects and due to non-collapsibility of these models, the
estimates are shrunk toward the null. Further, this model carries the most recent
longitudinal measures forward to the event time where as the longitudinal mea-
sures at the event time might be quite different from the most recent measures.
This is also caused the estimates to shrink towards 0. Next, the joint model
with univariate longitudinal biomarkers provides estimates that are closer to
the true values compared to the Cox model as the model is capable of detecting
baseline subject-specific β0i values as well as providing a good prediction of the
two biomarkers at time t by flexibly modeling the trajectory of the biomarkers.
Third, our joint multivariate longitudinal-survival model proposed here is ca-
pable of modeling multiple biomarkers simultaneously by taking the correlation
between the biomarkers and hence, leads to even closer coefficient estimates
compared to our joint univariate longitudinal-survival model.
5. Application of the Proposed Joint Multivariate Longitudinal
Survival Model to DaVita Data on Hemodialysis Patients
In this section, we apply our proposed joint multivariate longitudinal-survival
model to a specific study of hemodialysis patients discussed in introduction.
Here, we focus on a subset of data where every patient has at least 8 longitudinal
measures of albumin and at least 8 longitudinal measures of calcium. This subset
includes N = 929 hemodialysis patients with an overall censoring rate in the
data is 25.6%.
Although the longitudinal albumin and calcium biomarkers are supposed to
be measured during every lab visit, however, we noticed that in our study cohort,
on average at 12.4% of lab visits neither of these two biomarkers were measured.
We also noticed that on average in 26.8% of lab visits there were no measured
albumin biomarker and in 15.1% lab visits, there were no measured calcium
biomarker.
With the aim of testing the association between mortality and the value of the
biomarkers of interest, albumin and calcium, among hemodialysis patients, we
analyze the data once using last-observation carried forward Cox model, another
time using a univariate joint longitudinal-survival model (Uni. Joint Model), and
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finally using our recent multivariate joint longitudinal-survival model (Multi.
Joint Model). In order to adjust for potential confounder factors, other than
longitudinal albumin and calcium measures, we also include age, sex, race, a
baseline measure of phosphorus, and a baseline measure of iron.
Unlike the last observation carried forward Cox model that uses the most re-
cent albumin and calcium biomarker values as the values of these biomarkers at
each event time, our proposed joint longitudinal-survival models flexibly model
the trajectory of these biomarkers over time and at each event time, the models
impute the most relevant biomarker values according to the trajectories of those
biomarkers. Further, unlike the Cox model that marginalize covariate effects
across all subjects, our proposed joint models are capable of detecting differen-
tial subject-specific baseline hazards. Our univariate joint longitudinal-survival
method models the longitudinal albumin and calcium processes independently
of each other. Our proposed multivariate joint longitudinal-survival model intro-
duced in this paper, however, models the two processes simultaneously. Simul-
taneously modeling the two processes will allow a better longitudinal trajectory
specification as the model can borrow information from measurements of one
process when measurements of the other process are missing.
Table 5 shows the results of analyzing the data using the three models of
last-observation carried forward Cox, our proposed univariate joint longitudinal-
survival model, our proposed multivariate joint longitudinal-survival model. The
results from all three models consistently show that age and albumin value at
the time of death are significant risk factors of mortality among hemodialysis
patients. The results from the Cox model show that each 1 g/dL decrement in
albumin level corresponds to 3.4 times higher risk of death. The risk of death per
each 1 g/dL decrement in albumin is estimated to be 4.2 and 5.1 times higher
under our proposed univariate joint model and multivariate joint model, respec-
tively. Further, compared to the univariate joint model, the multivariate joint
model leads to 32% and 36% reduction in the 95% credible region of the esti-
mated effect of every one unit decrement in albumin and calcium, respectively.
This observation was expected as the multivariate joint model by simultane-
ously modeling albumin and calcium trajectories, estimate those trajectories
with higher precision compared with the univariate joint model.
6. Discussion
When monitoring the health of subjects, often times multiple risk factors are
measured over time. Collected longitudinal risk factors are often correlated with
each other as they are measures taken on the same subject. Modeling these
longitudinal risk factors simultaneously where the correlation between the risk
factors are taken into account can be beneficial, specially when there exists dif-
ferential measuring density in the collected risk factors. Further, the association
between the collected risk factors and the survival outcomes is often the practi-
tioners’ primary interest. In this paper, we proposed a joint longitudinal-survival
modeling framework with a longitudinal component capable of modeling mul-
tiple longitudinal processes simultaneously with the correlation between those
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LOCF Cox Model Uni. Joint Model Multi. Joint Model
No. of No. of Relative Risk Relative Risk Relative Risk
Covariates Cases Deaths (95% CI) (95% CR) (95% CR)
Age (10y) 929 691 1.33 (1.20,1.48) <.001 1.50 (1.33,1.68) 1.56 (1.35,1.76)
Sex
Men 546 412 1.0 1.0 1.0
Women 383 279 1.02 (0.78,1.32) 0.90 1.01 (0.72,1.41) 1.01 (0.73,1.41)
Race
White 489 337 1.0 1.0
Black 264 204 1.79 (0.90,3.58) 0.11 1.76 (0.82,3.69) 1.78 (0.84,3.76)
Hispanic 118 102 0.71 (0.40,1.25) 0.23 0.71 (0.39,1.26) 0.73 (0.37,1.28)
Other 58 48 0.55 (0.28,1.11) 0.10 0.57 (0.20,1.18) 0.58 (0.20,1.18)
Phosphorus
(mg/dL) 929 691 1.07 (0.99,1.17) 0.08 1.10 (0.99,1.23) 1.10 (0.99,1.23)
Iron
(g/dL) 929 691 0.99 (0.98,0.99) 0.002 0.98 (0.94,1.02) 0.98 (0.94,1.02)
Serum albumin(t)
(1-g/dL decrement) 929 691 3.36 (2.64,4.29) <0.0001 4.17 (2.78,5.72) 5.11 (3.86,6.29)
Calcium
(mg/dL) 929 691 1.09 (0.87,1.37) 0.45 1.19 (0.72,1.86) 1.27 (0.92,1.69)
Table 5
Results of analyzing the association between the longitudinal albumin and calcium
biomarkers and mortality among hemodialysis patients. A cohort of 929 hemodialysis
subjects were followed over a maximal follow-up time of 5 years. Three separate models of
last-observation carried forward Cox, univariate joint longitudinal-survival model, and
multivariate joint longitudinal-survival model were fit to the data.
processes taken into account. Our modeling framework is robust to common
distributional assumptions as by using the Bayesian non-parameteric Gaussian
process and Dirichlet process techniques, we avoid common functional and dis-
tributional assumptions in the model.
We used synthetic data in order to show the benefit of simultaneously mod-
eling the trajectories of multiple longitudinal processes using our proposed mul-
tivariate longitudinal model as opposed to separate independent longitudinal
models each modeling the trajectory of one longitudinal process independently
from other longitudinal processes. Our findings show that a multivariate model
has more precision in estimating the underlying trajectories of the longitudinal
risk factors. Next, using synthetic data we showed that our proposed joint mul-
tivariate longitudinal-survival model performs better in terms of mean-squared
error of the estimated survival coefficients compared to the modeling framework
we introduced elsewhere where the longitudinal biomarkers modeled indepen-
dently (Akhavan et al., 2018).
Our proposed modeling framework has some limitations. Our modeling frame-
work is limited to the proportional hazards models only. Further, our method is
computationally demanding and may not be scalable as number of subjects and
within-subject measurements increase. In future, our modeling framework can
be extended by relaxing the proportional hazard assumption on the survival
component. Also, one by using alternatives to the conventional MCMC tech-
niques, including variational methods can make our modeling framework more
computationally efficient.
In order to test the association between the longitudinal albumin and cal-
cium biomarkers and mortality among hemodialysis patients, we used data
on 929 hemodialysis patients. We analyzed the data using three models of
last-observation carried forward Cox model, the univariate joint longitudinal-
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survival model we proposed elsewhere (Akhavan et al., 2018), and the multi-
variate longitudinal-survival model that was proposed in this paper. While the
results are consistent across all models, our proposed multivariate joint model
that is capable of modeling the trajectory of longitudinal biomarkers with higher
precision, leads to stronger estimated biomarker with higher precision for the
estimated effect.
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Appendix A: Implementation
Consider the joint longitudinal-survival likelihood function, fL,S , introduced in
equation 3.1. Let ω be a vector of all model parameters with the joint prior
distribution π(ω). The posterior distribution of the parameter vector ω can be
written as
π(ω|X,Y ) ∝ fL,S × π(ω), (A.1)
where X and Y denote longitudinal and time-to-event data respectively, and
fL,S is the joint model likelihood function (equation 3.1).
The posterior distribution of the parameters in our proposed joint model is
not available in closed form. Hence, samples from the posterior distribution of
the model parameters are obtained via Markov Chain Monte Carlo (MCMC)
methods. In particular, we use the Hamiltonian Monte Carlo (Neal, 2011) to
draw samples from the posterior distribution. Prior distributions on parameters
of the joint model were explained in details under the longitudinal and survival
component specification, and we assume independence among model param-
eters in the prior (ie. π(ω) is the product of the prior components specified
previously). We provide further detail on less standard techniques for sampling
from the posterior distribution when using a multivariate GP prior and we
explain how to evaluate the survival portion of the likelihood function when
time-varying covariates are incorporated into the model.
A.1. Evaluation of the Longitudinal Likelihood
Consider equation (3.7) and equation (3.8) where we introduced a flexible lon-
gitudinal model to simultaneously model multiple longitudinal biomarkers by
using the Gaussian process prior. By marginalizing over W i in equation (3.7),
one can show
Xi|β
(L)
i0 , σ
2
1 , σ
2
2 ∼ N(β
(L)
i0 ,R⊗ Si +Σǫ). (A.2)
In order to sample from the posterior distribution of the parameters of the
joint longitudinal-survival model introduced in Section 3, at each iteration of
the MCMC, we need to compute the log posterior probability. Computing the
log posterior probability involves evaluation of log|R⊗Si+Σǫ| and (R⊗Si+
Σǫ)
−1. This requires a memory space of O(li
2) and a computation time of O(li
3)
per subject i. Consider matrix Si = κ
2
iKi, where the (i, j)
th element of K is
Ki(i, j) = exp{−ρ
2(tij − tij′ )
2}. Ki can be pre-computed prior to starting
the MCMC process. Further, by using the eigen-value decomposition technique,
one may make the calculation of the matrix determinant and inverse of the
covariance matrix more computationally efficient. Using a similar idea proposed
by Flaxman et al. (2015), we propose the following fast multivariate Gaussian
process computation approach. We start pre-computing the Ki matrix. Also,
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we can pre-compute the eigen-vale decomposition of this matrix prior to starting
the MCMC process. Consider an eigen-value decomposition of the following form
Ki = UΛU
T ,
where U is a matrix of eigen-vectors and Λ is a diagonal matrix of eigen-values.
For a scalar κ2i , the eigen-value decomposition of κ
2
iKi is of the form
Si = κ
2
iKi
= U(κ2iΛ)U
T .
At each iteration of the MCMC, one can obtain the eigen-value decomposition
of the matrix R,that is of the form
R = V DV T ,
where V is a matrix of eigen-vectors andD is a diagonal matrix of eigen-values.
One can then compute efficiently the log-determinant of the cross-covariance
matrix, log|R⊗ Si +Σǫ|, as
log|R⊗ Si +Σǫ| = log|(V DV
T )⊗ (U(κ2iΛ)U
T ) + Σǫ|
= log|(V ⊗ U)(D ⊗ κ2iΛ)(V ⊗ U)
T +Σǫ|
= log|(V ⊗ U)(D ⊗ κ2iΛ + Σǫ)(V ⊗ U)
T |
= log|(D ⊗ κ2iΛ) + Σǫ|
= 2li
2∑
k=1
li∑
j=1
log(dkkλjj + σ
2
1I[k == 1] + σ
2
2I[k == 2]),
(A.3)
and the inverse of the cross-covariance matrix, (R⊗Si+Σǫ)
−1, can be efficiently
computed as
(R⊗ Si +Σǫ)
−1 =
(
(V DV T )⊗ (U(κ2iΛ)U
T ) + Σǫ
)−1
=
(
(V ⊗ U)(D ⊗ κ2iΛ)(V ⊗ U)
T +Σǫ
)−1
=
(
(V ⊗ U)(D ⊗ κ2iΛ + Σǫ)(V ⊗ U)
T
)−1
=
(
(V ⊗ U)(D ⊗ κ2iΛ + Σǫ)
−1(V ⊗ U)T
)
, (A.4)
In equation (A.4), computation of the inverse of the term (D⊗κ2iΛ+Σǫ) in the
middle is very easy as it’s a diagonal matrix. Using our proposed efficient com-
putation technique introduced here, we noticed a 30 times faster computation
speed in our simulations.
A.2. Evaluation of the Survival Likelihood
We evaluate the survival likelihood using piece-wise integration. Consider the
survival time for subject i that is denoted by ti and is distributed according
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to a Weibull distribution with shape parameter τ and scale parameter exp(λi),
where λi = ζ
(S)Z
(S)
i + ζ
(L)Z
(L)
i (t), where Z
(S)
i and Z
(L)
i (t) are vectors of
covariates for subject i, with potentially time-varying covariates, corresponding
to the survival and the longitudinal covariates respectively, and ζ(S) and ζ(L)
are vectors of survival and longitudinal coefficients respectively. One can write
the hazard function hi(t) as
hi(t) = τt
τ−1exp(λi − exp(λi)t
τ ). (A.5)
The survival function Si(t) can be written as
Si(t) = exp{−
∫ t
0
hi(w)dw}.
Consider survival data on n subjects, some of whom may have been censored.
Let event indicator δi that is 1 if the event is observed, and 0 otherwise. The
survival likelihood contribution of subject i can be written in terms of the the
hazard function hi(t) and the survival function Si(t) as
f
(i)
S|L = hi(ti)
δiSi(ti)
= hi(ti)
δie−
∫ ti
0 hi(w)dw.
The overall survival log-likelihood can be written as
log(L) =
n∑
i=1
log(f
(i)
S|L)
=
n∑
i=1
(
δilog(hi(ti))−
∫ ti
0
hi(w)dw
)
.
The hazard function in the equation (A.5) includes some time-varying covariates
which often makes the integral of the hazard function non-tractable. In this case,
one can estimate the integral using rectangular integration.
A.3. A Mutivariate Gaussian Process Model for Modeling
Non-Overlapping Biomarker Measures
Consider two longitudinal biomarkers X(1) and X(2), each with l
(1)
i and l
(2)
i lon-
gitudinal measures respectively. The obtained longitudinal measures need not
to be taken at the same time for both biomarkers. The two biomarkers may or
may not have any measurement time overlap. Consider biomarker observed time
points of the form t
(1)
ij , j = 1, 2, . . . , l
(1)
i and t
(2)
ik , k = 1, 2, . . . , l
(2)
i for biomarker1
and biomarker2, respectively. Define t˜ij as a set of unique time points out of a
pool of all biomarker observed times from both biomarkers. Define li as the num-
ber of unique time-points t˜ij . It’s obvious that max{l
(1)
i , l
(2)
i } ≤ li ≤ l
(1)
i + l
(2)
i .
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Also, out of all the li unique time points, l
(1)
i one of them are the measurement
time points where the biomarker 1 measure were obtained and l
(2)
i of them are
when the biomarker 2 measurements were obtained. For biomarker 1, biomarker
measurements at the remaining (li − l
(1)
i ) time points can be treated as miss-
ing values. Similarly, for biomarker 2, there are (li − l
(2)
i ) missing biomarker 2
measured values. One can consider a similar model as in equation (3.9), where
observed biomarkers column vector Xi includes (li − l
(1)
i ) missing values for
biomarker 1 and (li − l
(2)
i ) missing values for biomarker2. Despite some missing
biomarker measures at some time-points, cross-covariance function can be fully
specified as it only depends on observed time points t˜i which are all observed.
Under the Bayesian inference, any missing data point can be represented as
a parameter that can be estimated using posterior samples in the same way as
any other parameter in the model (Gelman et al., 2014). Hence, our modeling
approach introduced in Section 3 is not limited at all to overlapping biomarker
measures, and can cover a general case where obtained biomarker measures
may or may not overlap in time. In non-overlapping case, additional missing
biomarker values are introduced in the problem that are treated as parameters
and can be easily estimated using posterior samples of those parameters.
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